MECHANISMS TO ENHANCE CYTOLYTIC T CELL RESPONSES TO HIV
增强溶细胞 T 细胞对 HIV 反应的机制
基本信息
- 批准号:2887889
- 负责人:
- 金额:$ 24.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-09-29 至 2000-09-28
- 项目状态:已结题
- 来源:
- 关键词:AIDS vaccines antigen presentation antigen presenting cell cytokine cytotoxic T lymphocyte gag protein gene mutation histocompatibility antigens human immunodeficiency virus 1 laboratory mouse microorganism culture microorganism immunology nonhuman therapy evaluation plasmids vaccine development vector vaccine virus DNA virus antigen
项目摘要
DESCRIPTION (Adapted from applicant's abstract): This research is focused
on mechanisms to enhance the cytolytic response to HIV-1 antigens, with the
goal of developing a clinically effective vaccine against HIV-1. Two novel
advances underlie the application of this research to HIV-1. (1) A strategy
has been developed for targeting gene products of DNA vaccines to a cellular
trafficking pattern that accesses the major histocompatibility class II (MHC
II) pathway for processing and presentation of antigenic epitopes to the
helper T cell arm of the immune response mechanism. This targeting of
antigen has been shown to result in a marked enhancement of the cytolytic
immune response to the antigen. (2) A non-viral system for in vivo delivery
of genes as a DNA-gelatin nanosphere coacervate is being applied for the
delivery of the DNA vaccine to antigen-presenting cells, and for the
co-delivery of cytokines that augment the Th1 CD4+ subset of helper T cells
so as to potentiate the cytolytic T cell response of the immune system. The
principle goals of the proposed research are to perfect these systems with
the HIV-1 gag protein as the initial antigen, and to prove the feasibility
of these approaches so that they may be considered for human clinical
trials.
The research design is, first, to prepare DNA expression plasmid constructs
encoding a chimeric gag protein containing the signal, transmembrane and
cytoplasmic targeting sequences of the LAMP lysosomal membrane protein, and
to test mice vaccinated with the plasmid as naked DNA for the expected
enhanced presentation of the antigen to CD4+ helper T cells and augmented
cytolytic T cell response. The experiments also will test the effect on the
immune response of modifications of the gag gene required for nuclear
transport of the mRNA in the absence of the rev gene: gag gene constructs
containing mutations in the INS inhibitory instability elements, the simian
retrovirus type 1 constitutive transport element (CTE), or a combination of
the two. Next, after selection of the appropriate plasmid construct, the
DNA will be incorporated into nanospheres to study the cytolytic response of
the mouse vaccinated with nanospheres as compared to naked DNA, and to
perfect the nanosphere formulation for this application as a vaccine.
Finally, the appropriate formulation will be tested for the co-delivery with
gag DNA of cytokines, especially IL-2, IL-12, gamma-INF and GMCSF, in the
augmentation of the cytolytic response.
描述(改编自申请人摘要):本研究的重点是
增强对HIV-1抗原的细胞溶解反应的机制,
目标是开发一种临床有效的HIV-1疫苗。 两种新型
这些进展是这项研究应用于HIV-1的基础。 (1)一项战略
已经开发了用于将DNA疫苗的基因产物靶向至细胞的DNA疫苗。
进入主要组织相容性II类(MHC)的运输模式
II)用于加工和呈递抗原表位至细胞的途径
辅助性T细胞的免疫反应机制。 这种针对
抗原已显示导致细胞溶解性的显著增强,
对抗原的免疫反应。 (2)用于体内递送的非病毒系统
作为DNA-明胶纳米球凝聚体的基因被应用于
将DNA疫苗递送至抗原呈递细胞,以及
增加辅助性T细胞的Th 1 CD 4+亚群的细胞因子的共递送
从而增强免疫系统的溶细胞性T细胞应答。 的
拟议研究的主要目标是完善这些系统,
以HIV-1 gag蛋白为起始抗原,
这些方法,使他们可以考虑为人类临床
审判
本研究的设计是,首先,制备DNA表达质粒构建体,
编码含有信号的嵌合gag蛋白,跨膜和
LAMP溶酶体膜蛋白的细胞质靶向序列,和
为了测试用质粒作为裸DNA接种的小鼠,
增强抗原向CD 4+辅助性T细胞的呈递,
溶细胞T细胞应答。 实验还将测试对
免疫应答的修饰的gag基因所需的核
在不存在rev基因时mRNA的转运:gag基因构建体
含有INS抑制性不稳定元件突变的猿猴,
逆转录病毒1型组成型转运元件(CTE),或
the two. 接下来,在选择合适的质粒构建体后,
将DNA掺入纳米球中以研究DNA的细胞溶解反应。
与裸DNA相比,用纳米球接种的小鼠,
完善了纳米球制剂作为疫苗的应用。
最后,将测试适当的制剂与以下物质的共递送:
细胞因子,特别是IL-2,IL-12,γ-INF和GMCSF的gag DNA,在
细胞溶解反应的增强。
项目成果
期刊论文数量(6)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Regulation of HIV-Gag expression and targeting to the endolysosomal/secretory pathway by the luminal domain of lysosomal-associated membrane protein (LAMP-1) enhance Gag-specific immune response.
HIV-Gag 表达的调节以及溶酶体相关膜蛋白 (LAMP-1) 的管腔结构域靶向内溶酶体/分泌途径可增强 Gag 特异性免疫反应。
- DOI:10.1371/journal.pone.0099887
- 发表时间:2014
- 期刊:
- 影响因子:3.7
- 作者:Godinho,RodrigoMacieldaCosta;Matassoli,FlavioLemos;Lucas,CarolinaGonçalvesdeOliveira;Rigato,PaulaOrdonhez;Gonçalves,JorgeLuizSantos;Sato,MariaNotomi;MacielJr,Milton;Peçanha,LigiaMariaTorres;August,JThomas;MarquesJr,Ernes
- 通讯作者:MarquesJr,Ernes
DNA encoding an HIV-1 Gag/human lysosome-associated membrane protein-1 chimera elicits a broad cellular and humoral immune response in Rhesus macaques.
- DOI:10.1371/journal.pone.0000135
- 发表时间:2006-12-27
- 期刊:
- 影响因子:3.7
- 作者:Chikhlikar P;Barros de Arruda L;Maciel M;Silvera P;Lewis MG;August JT;Marques ET
- 通讯作者:Marques ET
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
J. Thomas August其他文献
J. Thomas August的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('J. Thomas August', 18)}}的其他基金
Dengue Epitope Vaccine,Tetravalent & MHCII-Targeted
登革热表位疫苗,四价
- 批准号:
6800157 - 财政年份:2003
- 资助金额:
$ 24.3万 - 项目类别:
Dengue Epitope Vaccine,Tetravalent & MHCII-Targeted
登革热表位疫苗,四价
- 批准号:
7098729 - 财政年份:2003
- 资助金额:
$ 24.3万 - 项目类别:
Dengue Epitope Vaccine,Tetravalent & MHCII-Targeted
登革热表位疫苗,四价
- 批准号:
6887342 - 财政年份:2003
- 资助金额:
$ 24.3万 - 项目类别:
Dengue Epitope Vaccine,Tetravalent & MHCII-Targeted
登革热表位疫苗,四价
- 批准号:
7265158 - 财政年份:2003
- 资助金额:
$ 24.3万 - 项目类别:
Dengue Epitope Vaccine,Tetravalent & MHCII-Targeted
登革热表位疫苗,四价
- 批准号:
6689198 - 财政年份:2003
- 资助金额:
$ 24.3万 - 项目类别:
NOVEL TECHNOLOGIES APPLIED TO A DENQUE DNA VACCINE
DENQUE DNA 疫苗应用新技术
- 批准号:
6286101 - 财政年份:2000
- 资助金额:
$ 24.3万 - 项目类别:
ADVANCES IN DNA VACCINES AGAINST EBOLA & DENGUE VIRUSES
埃博拉 DNA 疫苗的进展
- 批准号:
6170768 - 财政年份:1999
- 资助金额:
$ 24.3万 - 项目类别:
ADVANCES IN DNA VACCINES AGAINST EBOLA & DENGUE VIRUSES
埃博拉 DNA 疫苗的进展
- 批准号:
6374080 - 财政年份:1999
- 资助金额:
$ 24.3万 - 项目类别:
ADVANCES IN DNA VACCINES AGAINST EBOLA & DENGUE VIRUSES
埃博拉 DNA 疫苗的进展
- 批准号:
2823952 - 财政年份:1999
- 资助金额:
$ 24.3万 - 项目类别:
MECHANISMS TO ENHANCE CYTOLYTIC T CELL RESPONSES TO HIV
增强溶细胞 T 细胞对 HIV 反应的机制
- 批准号:
2751266 - 财政年份:1998
- 资助金额:
$ 24.3万 - 项目类别:
相似海外基金
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - Supplement
定义实验性 AD 和 Tau 病中 MHC I 类限制性抗原呈递至 CD8 T 细胞 - 补充
- 批准号:
10836880 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
Targeting MAL2-mediated endocytosis to enhance tumor cell antigen presentation
靶向 MAL2 介导的内吞作用以增强肿瘤细胞抗原呈递
- 批准号:
10734324 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
- 批准号:
10740465 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
Investigation of Target Protein Degradation and Its Effect on Enhancing Cancer-Specific Antigen Presentation by Quantitative Mass Spectrometry
通过定量质谱研究靶蛋白降解及其对增强癌症特异性抗原呈递的影响
- 批准号:
23K04971 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Promoting cancer cells' antigen presentation for serving as better targets for T cell immunotherapy
促进癌细胞的抗原呈递,作为 T 细胞免疫治疗的更好靶点
- 批准号:
2885451 - 财政年份:2023
- 资助金额:
$ 24.3万 - 项目类别:
Studentship
Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
结直肠癌免疫治疗中靶向免疫蛋白酶体介导的抗原呈递
- 批准号:
10385926 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别:
Lipid Antigen Presentation as a Driver of T2D Inflammation
脂质抗原呈递作为 T2D 炎症的驱动因素
- 批准号:
10509043 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10704008 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别:
Sex Differences in lipid antigen presentation, impact of lipid antigen presentation on peripheral lipid metabolism
脂质抗原呈递的性别差异,脂质抗原呈递对外周脂质代谢的影响
- 批准号:
10818273 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别:
Enhancing antigen presentation in triple negative breast cancers through CD40 agonist, Flt3 ligand, and anthracycline chemotherapy
通过 CD40 激动剂、Flt3 配体和蒽环类化疗增强三阴性乳腺癌的抗原呈递
- 批准号:
10349397 - 财政年份:2022
- 资助金额:
$ 24.3万 - 项目类别: